Industry Briefs: July 16, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
DSM Pharmaceutical Products has signed a biologics contract manufacturing agreement with Recepta Biopharma, based in Brazil. The contract covers the process development and cGMP manufacture by DSM of one of Recepta’s lead antibodies at DSM’s facilities in Groningen, the Netherlands. Read More
Verastem has formed a research collaboration with Eisai for small-molecule Wnt inhibitors. Read More
People News
AstraZeneca has reported on the terms of David Brennan’s retirement. As previously announced, Brennan relinquished his responsibilities as CEO and executive director on June 1, 2012. Brennan received a lump sum payment of £914,122 ($1.43 million) in lieu of contractual notice, representing 11 months’ base pay. Read More
Pharmaceutical Product Development has named Louis Renzetti vice-president of strategic laboratory operations. Read More
Pharmanet/I3 has appointed Robert Lasser as vice-president and general manager of neuroscience. Read More
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
